Revisit of metformin treatment in polycystic ovarian syndrome.
Polycystic ovary syndrome (PCOS) is a common endocrinopathy in women; its traditional pharmacological therapy mainly addresses short-term symptom control and does not correct the associated long-term metabolic risks. Recently, there has been increasing evidence that insulin resistance has an important implication in the pathogenesis of PCOS and that insulin-sensitizing drugs are a useful therapeutic approach. Therefore this review aims to discuss the current evidence on the use of metformin, a commonly used insulin-sensitizing agent, in treating both the short-term and the long-term problems of women with PCOS.
Lam
P M
PM
Departments of Obstetrics and Gynecology, Prince of Wales Hospital, Shatin, Hong Kong SAR, China.
Cheung
L P
LP
Haines
C
C
D002318:Cardiovascular Diseases; D003920:Diabetes Mellitus; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D008687:Metformin / Q000627:therapeutic use*; D010060:Ovulation; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy*; D011247:Pregnancy
D007004:Hypoglycemic Agents; D008687:Metformin